CCNK and cancer: By analyzing the correlation between small-molecule resistance of cancer cell lines and mRNA levels of Ub ligase components, Słabicki et al. (57) identified CR8, a CDK inhibitor, as the candidate molecular glue degrader for cyclin K (also termed CCNK).